Novo Nordisk's oral Wegovy pill launched in the US in January 2026

Novo Nordisk's oral Wegovy pill reached the US market in January 2026, becoming the first oral GLP-1 approved for obesity ^[2]. Early prescription data show the launch drew in a large share of people who had not been using GLP-1 drugs before.

IQVIA, a health data company, reported that within eight weeks of launch, oral Wegovy accounted for about one-third of new-to-brand prescriptions in the category, with most volume flowing through cash-pay channels. About two-thirds of that volume came from users new to any GLP-1 therapy. IQVIA said that pattern suggests convenience and lower prices are expanding the market rather than simply pulling patients off injectables ^[2].

Novo Nordisk's financial report for the first half of 2026 gives later figures. For the week ending 17 July, weekly prescriptions for the Wegovy pill exceeded 265,000, and total Wegovy prescriptions that week were around 575,000 ^[1]. The company said more than 5 million Wegovy pill prescriptions had been filled since launch, and that by new patient starts the Wegovy franchise remains the market leader among branded obesity medicines in the US ^[1].

The pill brought in DKK 3,218 million in the second quarter of 2026 and DKK 5,474 million in the first half, while adjusted obesity care sales rose 19% at constant exchange rates over the half-year ^[1]. Novo Nordisk raised its 2026 outlook, pointing to increased expectations for GLP-1 product sales ^[1]. The financial report did not state a list price for the pill or say how many US pharmacies stock it.

Regulators outside the US have also cleared the product. Oral Wegovy was approved in the UAE and the UK in June and in the European Union in July, based on OASIS 4 data showing up to 16.6% mean weight loss, and the company said more launches in other markets are planned ^[1]. A higher-dose Wegovy injection, Wegovy HD (semaglutide 7.2 mg), launched in the US in April and was approved in the US, UK and EU, based on STEP UP data showing up to 20.7% mean weight loss ^[1].

Competition is arriving. Eli Lilly's Foundayo (orforglipron), an oral small-molecule GLP-1, reached the US market in April 2026 ^[2]. Outside the US, semaglutide is losing patent exclusivity in several large markets during 2026, including India, where that happened on 20 March 2026, plus China, Brazil, Turkey and Canada. Those countries together hold 38% of adults living with obesity, according to IQVIA ^[2]. IQVIA forecasts the global obesity medicines market at $92 billion in list-price sales in 2026, up from $66 billion in 2025 ^[2].

Why it matters for patients

The launch adds a pill option to a category that had been injection-only in the US, and early data suggest it is reaching people who were not already on a GLP-1 ^[2]. That matters for the roughly two-thirds of early users who are new to the drug class ^[2].

Most early volume moved through cash-pay channels ^[2], so the out-of-pocket price largely determines who can use it. That price has not been disclosed in the company's financial report. IQVIA notes that with semaglutide going off patent in several self-pay markets outside the US, price and consumer access will shape what happens next ^[2]. It also reports that patients most often cite tolerability as the reason they stop GLP-1 treatment, which makes staying on therapy over time a practical question regardless of which product someone starts ^[2].

What happens next

Novo Nordisk says additional Wegovy pill launches in other countries are planned in the coming quarters, and that the Wegovy 7.2 mg single-dose pen will roll out across the EU in the second half of 2026 ^[1]. IQVIA expects the next phase of competition from 2027 to 2028, with Eli Lilly's retatrutide, Boehringer Ingelheim's survodutide and Amgen's MariTide arriving, and projects that real-world studies such as SCoMIS, due to report by 2029, and SURMOUNT-REAL will test whether these drugs deliver broader health-system benefits ^[2].